chemically-modified mRNA [1] [2] [3] [4] . Nucleic acid therapy has great potential for the treatment of a 68 wide range of diseases [5] , however, only a small number of formulations used in vitro, make it 69 to clinical trials as there are a number of barriers to in vivo delivery and transfection [4, 6] . 70
Previously, we described the use of liposome-peptide receptor-targeted nanoparticles (RTNs) for 71 both in vitro [7] [8] [9] [10] [11] and in vivo [12] [13] [14] [15] [16] [17] [18] nucleic acid delivery to various sites and targets in the 72 body. These lipopolyplexes are capable of inducing nucleic acid compaction and their protection 73 against premature degradation in biological fluids. 74
There is always a need to improve the performance of delivery vehicles and giant 75 unilamellar vesicles (GUVs) have some interesting properties for the development of functional 76 nucleic acid delivery systems with tunable properties [19, 20] . Earlier, DNA-directed self-77 assembly of GUVs has been shown, where DNA was introduced to vesicular surface by covalent 78 conjugation [21] [22] [23] [24] . These GUVs, also proved to be invaluable in vitro tools for the mechanistic 79 understanding of complex and integrated biophysical and biomembrane processes [25] [26] [27] [28] [29] [30] [31] [32] . Here, 80 we exploit the bilayer properties of GUVs as the starting platform for self-assembly of a new 81 generation of safe and stable lipid-peptide-nucleic acid transfectants with improved biological 82 performance through the introduction of sugars for improved stabilization as well as targeting 83 peptide ligands [20] . Indeed, the difference in density between the equiosmolar monosaccharidic 84 intervesicular (external) and the disaccharidic intravesicular (internal) aqueous solutions offer 85 vesicular stabilization and shape uniformity [33] as well as optical contrast. In addition, it is 86 known that cationic transfectants can induce bioenergetic crisis, which dependent on cell type 87 and mitochondrial polarization state it may initiate cell death [34] . The sugars associated with the 88 engineered GUVs (e.g. glucose) could potentially help in re-establishing homeostasis with 89 increased ATP synthesis, thereby overcoming cytotoxicity pertaining to cationic lipoplexes and 90
lipopolyplexes. 91
GUVs carrying nucleic acids may exhibit limited cell uptake and transfection efficacy 92 due to their large size compared with conventional large unilamellar vesicles [35] by addition of ice-cold sample-diluent provided in the assay kit containing 25mM EDTA. 255
Nanocomplexes were removed by centrifugation, and complement activation products were 256 measured in ELISA kits. Control serum incubations contained buffers that were used for 257 liposome suspension. Zymosan was prepared as described before [41] and was used as a positive 258 control for generating C5a and sC5b-9 at a concentration of 0.2 mg/mL. 
Statistical analysis 306
The data presented in this study are expressed as the mean ± standard deviation (SD) and 307
were analyzed using a two-tailed, unpaired Student's t-test or one-way analysis of variance and 308
Bonferroni's post hoc analysis, where applicable. first. Nanovesicles were considerably larger than their liposomal counterparts (557.0 ± 82.5 nm 315 vs 76.1 ± 0.9 nm, respectively) consisting of two particle populations ( Fig. S1 ) and had 316 comparable average zeta potential values (66.9 ± 1.7 mV for nanovesicles vs 70.9 ± 2.4 mV for 317 liposomes, respectively). These nanovesicles were capable of forming complexes with peptide 318 and nucleic acid (DNA or siRNA) of 89.6 ± 1.3 nm, when mixed with DNA, or under 140 nm, 319 when mixed with siRNA, respectively ( Fig. 1A and Fig. S1 ). There was no statistical difference 320 in the size of the nanocomplexes, however, LYDves had the least cationic surface charge among 321 all nanocomplexes (zeta potential of 26.2 ± 0.4 mV for LYDves vs 47.7 ± 3.0 mV for LYD). 322
Negative staining transmission electron microscopy (TEM) was used to further 323 characterize nanovesicles (Fig. 1B) and nanovesicle complexes (LYDves; Fig. 1C ). Nanovesicles 324 and nanovesicle complexes were predominantly spherical, however, some rod-shaped objects 325
were also present (in LYDves; Fig. 1C ). The majority of the spherical entities observed by TEM 326 for each formulation were in similar size ranges determined by dynamic light scattering (DLS). 327 DOTMA/DOPE liposomes and LYD lipopolyplexes were also visualized ( Fig. S2 ) and they 328 formed some discrete spherical particles with most being aggregated in clusters. These clusters 329 may have been generated during sample preparation and dehydration processes for TEM. 330
The ability of nanocomplexes to package DNA efficiently and to dissociate following 331 heparin challenge was assessed (Fig. 1D) . PicoGreen-labelled DNA was formulated into cationic 332 LYD and LYDves. Packaging was inferred from fluorescence quenching compared with free 333 DNA as 100%. The packaging efficiency refers to the extent of nucleic acid protection. 334 Therefore, the higher the packaging efficiency, the better the protection of the nucleic acid cargo. 335
Both formulations resulted in high packaging efficiency: 81% for LYD lipopolyplexes compared 336 with 94% for LYDves nanovesicle complexes. In addition, they had a different heparin release 337 profile. LYD achieved 50% dissociation at 0.41 U/mL heparin, whereas LYDves achieved 50% 338 dissociation at 0.84 U/mL heparin, thus making the latter less responsive to polyanions. 339 formulations with the targeted peptides resulted in a much higher uptake than those with non-363 targeted peptides (p<0.001 for all comparisons), however, this effect was more pronounced with 364 the nanovesicle complexes. For example at 24 h, LYRves resulted in approximately 10-fold higher 365 uptake than LK16Rves, which was considerably higher than the difference in uptake of LYR, 366 which in turn was 2.6-fold higher than that of LK16R. 367
Flow cytometry analysis (Fig. 2C) , showed a similar uptake pattern to that of in-cell 368
Western analysis at 4 h post transfection. The comparisons described above as being significant 369 ( Fig. 2A-B) were also significant in Fig. 2C . For example, the targeted formulations resulted in a 370 much higher uptake than their non-targeted counterparts (p<0.001 for all comparisons), however 371 again this effect was more pronounced with the nanovesicle complexes. FACS analysis was also 372 13 performed to investigate the uptake of Cy3-labelled DNA nanocomplexes in Neuro-2A cells. 373
The trend was the same as the one found for siRNA uptake; again there was no statistical 374 difference between nanovesicle complexes and lipopolyplexes at 24 h and the use of targeting 375 peptides resulted in higher uptake than non-targeting formulations (Fig. S3) . However, PR and 376 peptide/DNA (PD) complexes showed a significantly different nucleic acid uptake profile. For 377 example at 4 h post-transfection, PD complexes (Fig. S3 ) achieved 22.5% uptake, which was 378 significantly more than the 4.1% seen with the PR formulations ( Fig. 2C; p<0.05) . 379 380 3.3. In vitro transfection efficiencies. Nanocomplexes were formulated and used for 381 transfection of Neuro-2A and HBE cells (Fig. 3) . LMED formulations were significantly better 382 in transfection than the LMEDves (p<0.05) in Neuro-2A cells (Fig. 3A) , however, this difference 383
was not statistically significant for LYD and LYDves nanocomplexes in HBE cells (Fig. 3B) . 384
Importantly, the receptor-targeted formulations showed considerable differences in transfection 385 efficiency compared with the non-targeted formulations. (Fig. 3C) and LMED (Fig. 3D) nanocomplexes provided  394 evidence of the high transfection efficiency of both formulations. Flow cytometry analysis of 395 GFP transfections was then performed (Fig. 4) and showed that 28.6 ± 1.9% and 33.5 ± 2.2% of 396 cells expressed GFP following transfection with LMEDves and LMED, respectively (p<0.05). 397 398 3.4. Complement activation assay and cell viability. We challenged undiluted human 399 serum with LYD and LYDves formulations and measured the two pathway-independent soluble 400 end-point complement activation products C5a and sC5b-9, respectively [39, 42]. The 401 complement system is a key effector of both innate and cognate immunity recognizing danger 402 signals through pattern recognition [43] . C5a is an anaphylatoxin and chemoattractic agent, 403 14 whereas soluble sC5b-9 is a measure of whole complement activation. The results in Fig. 5A  404 show that neither formulations elevated sC5b-9 levels above the background compared on the 405 basis of equivalent surface area. On the other hand, both formulations caused very small 406 increases of serum C5a levels (Fig. 5B) . For comparison zymosan treatment induced massive 407 rises of C5a and sC5b-9 levels above background (201.3 ± 10.1 ng/mL C5a and 31.7 ± 1.6 408 g/mL sC5b-9, respectively). On the basis of our findings, our formulations were poor activators 409 of the complement system and could be used for intravenous applications. Indeed, the extent of 410 complement activation by these preparations was considerably lower than PEGylated regulatory 411 approved liposomes (Doxil) on equivalent surface area (46 cm 2 ) basis (8560 ± 108.1 ng/mL 412 sC5b-9) [44] . 413
The cell viability assessment showed no particular differences between nanocomplexes, 414 which included lipopolyplexes and nanovesicle complexes ( to the airways of murine lungs (Fig. 6 ). 24 h after administration, luciferase assay was performed 424 on lung extracts. The mean luciferase expression from LEDves was higher than that of LED (6160 425 RLU/mg protein for LEDves vs 4596 RLU/mg protein for LED), but this was not statistically 426
significant. 427
Finally, we investigated whether LMERves nanocomplexes can be delivered to tumours 428 following systemic administration in xenograft mouse models of neuroblastoma. 24 h after 429 intravenous administration, the organs and the tumours were removed and imaged using the IVIS 430 III system for siRNA-Dy677 distribution. The LMERves nanocomplexes showed high retention in 431 tumours (17.5% of the initial injected dose; the radiant efficiency of the initial dose was 432 measured at 1.9 x 10 10 photons s −1 cm −2 steradian −1 per μW cm −2 ), while leaving other normal 433 tissues with extremely low (heart, liver, kidneys and spleen) or moderate uptake (lung; 5.2% of 434 the initial injected dose) (Fig. 7A-B) . The fluorescent radiant efficiency was 3.39-fold higher in 435 tumours than in the lungs (Fig. S4, p<0.01) . Immunostaining of the tumours (Fig. 7C-H procedures [19, 23, 26, 47, 67, 68] . Here, we initially modified the procedure of making GUVs 532 that resulted in nanovesicles of less than 1 µm in size and then for the first time, we reported the 533 development of nanovesicle complexes using these nanovesicles (derived from GUV 534 precursors). These engineered vesicles exhibited good transfection efficiency, however, unlike 535 conventional cationic lipoplexes, nanovesicles and nanovesicle complexes neither exhibited 536 considerable cytotoxicity nor activated the complement system. These observations are of 537 importance, since nanovesicle complexes were able to deliver nucleic acids to both lung and 538 tumour tissues in vivo. Nanovesicle complexes therefore represent a promising tool for 539 improving our arsenal of safer non-viral vectors for site-specific delivery of therapeutic nucleic 540 
